A press release issued by California Trim Clinic, a Westlake Village telemedicine and compounding practice, says KPV has been named in a new 2026 HHS draft interim enforcement-discretion policy covering certain patient-specific 503A peptide compounding.

KPV is a tripeptide, three amino acids long, built from lysine, proline and valine. The research behind it is old and almost entirely preclinical: a 2008 Gastroenterology study examined KPV transport through the PepT1 transporter using human-derived intestinal epithelial cells, immune cells and mouse models, and a separate 2008 mouse study looked at KPV in experimental inflammatory bowel disease models.

What the policy actually covers

HHS lists KPV alongside BPC-157, Epitalon, MOTS-c, Semax and TB-500 as peptide bulk drug substances addressed by the draft framework while FDA continues formal 503A rulemaking. For KPV the scope is narrow: KPV acetate, in oral and topical dosage forms, when the policy's other conditions on product quality, documentation, patient-specific prescriptions and adverse-event reporting are met.

That narrowness is the part most likely to get lost. The release itself makes the point that "KPV is covered" is too broad a statement, and that an injectable or multi-peptide blend should not be represented as falling inside the same scope.

The gaps FDA named

FDA reviewed KPV free base and KPV acetate at the July 23, 2026 Pharmacy Compounding Advisory Committee meeting, considering wound healing and inflammatory conditions among the proposed uses. At that point the agency had identified significant information gaps, including limited human exposure data and uncertainty about potential safety issues in humans.

HHS later said the record included additional material on historical use, lot-specific characterization of KPV acetate, and endotoxin and microbial testing, and noted the committee voted in favor of inclusion. Enforcement discretion is not approval, and the release says so plainly: compounded medications are not FDA-approved, and FDA does not evaluate them for safety, effectiveness or quality before marketing.

Bottom line

This is a press release from a clinic that sells peptide programs, and the commercial interest is obvious. The underlying regulatory fact is still worth knowing, and the honest version of it is that a federal pathway got slightly clearer while the human evidence for KPV did not move at all.